Department of Clinical Pathological Biochemistry, Faculty of Pharmaceutical Science, Doshisha Women's College of Liberal Arts, 97-1 Kodo Kyo-tanabe, Kyoto 610-0395, Japan.
Int J Mol Sci. 2019 Jan 31;20(3):619. doi: 10.3390/ijms20030619.
Systemic sclerosis (SSc) is a connective tissue disease of autoimmune origin characterized by vascular dysfunction and extensive fibrosis of the skin and visceral organs. Vascular dysfunction is caused by endothelial cell (EC) apoptosis, defective angiogenesis, defective vasculogenesis, endothelial-to-mesenchymal transition (EndoMT), and coagulation abnormalities, and exacerbates the disease. Fibrinolytic regulators, such as plasminogen (Plg), plasmin, α2-antiplasmin (α2AP), tissue-type plasminogen activator (tPA), urokinase-type plasminogen activator (uPA) and its receptor (uPAR), plasminogen activator inhibitor 1 (PAI-1), and angiostatin, are considered to play an important role in the maintenance of endothelial homeostasis, and are associated with the endothelial dysfunction of SSc. This review considers the roles of fibrinolytic factors in vascular dysfunction of SSc.
系统性硬化症(SSc)是一种自身免疫性结缔组织疾病,其特征为血管功能障碍和皮肤及内脏器官广泛纤维化。血管功能障碍是由内皮细胞(EC)凋亡、血管生成缺陷、血管生成缺陷、内皮向间充质转化(EndoMT)和凝血异常引起的,并使疾病恶化。纤溶调节因子,如纤溶酶原(Plg)、纤溶酶、α2-抗纤溶酶(α2AP)、组织型纤溶酶原激活剂(tPA)、尿激酶型纤溶酶原激活剂(uPA)及其受体(uPAR)、纤溶酶原激活物抑制剂 1(PAI-1)和血管抑素,被认为在维持内皮稳态方面发挥着重要作用,并与 SSc 的内皮功能障碍有关。本文综述了纤溶因子在 SSc 血管功能障碍中的作用。